RecruitingNot ApplicableNCT05867381

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History

Sponsor

University of Southern California

Enrollment

112 participants

Start Date

Jul 11, 2023

Study Type

INTERVENTIONAL

Conditions

Atherosclerosis Air Pollution

Summary

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

Eligibility

Min Age: 65 YearsMax Age: 84 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called HEPA filtration and a medical device called Sham filtration for people with air pollution and atherosclerosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years to 84 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.